Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Rheumatoid Arthritis

Rheumatoid Arthritis

Part of Arthritis

Subtypes of Rheumatoid Arthritis

Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease 1 Elderly-onset rheumatoid arthritis 1

106 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Rheumatoid Arthritis

781 trials tracked for Rheumatoid Arthritis: 364 in phase 3 or 4 and 141 with published results. The most-cited published study has 396 citations.

781Trials tracked
364Phase 3 & 4
0Recruiting
141With published results
Phase distribution
Phase 4 95 Phase 3 269 Phase 2 161 Phase 1 39 Other / NA 217
  1. Phase 3 Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis Completed · 396 cited
  2. Phase 3 Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment Completed · 327 cited
  3. Phase 3 Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis Completed · 302 cited
  4. Phase 3 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis Completed · 282 cited
  5. Phase 3 Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients Completed · 270 cited
  6. Phase 3 A Moderate to Severe Rheumatoid Arthritis Study Completed · 259 cited
Show 44 more trials
  1. Phase 4 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Completed · 234 cited
  2. Phase 3 A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy Completed · 229 cited
  3. Phase 3 Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis Completed · 217 cited
  4. Phase 3 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis Completed · 216 cited
  5. Phase 3 To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) Completed · 212 cited
  6. Phase 3 Efficacy Study Of Tofacitinib In Pediatric JIA Population Completed · 191 cited
  7. Phase 3 Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis Completed · 186 cited
  8. Phase 3 Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) Completed · 185 cited
  9. Phase 4 Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate Completed · 181 cited
  10. Phase 3 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis Completed · 167 cited
  11. Phase 3 A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy Completed · 166 cited
  12. Phase 4 The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Completed · 164 cited
  13. Phase 3 An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Completed · 164 cited
  14. Phase 3 A Study in Moderate to Severe Rheumatoid Arthritis Completed · 164 cited
  15. Phase 3 A Study in Participants With Moderate to Severe Rheumatoid Arthritis Completed · 163 cited
  16. Phase 3 A Study in Moderate to Severe Rheumatoid Arthritis Participants Completed · 163 cited
  17. Phase 3 A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA) Completed · 163 cited
  18. Phase 3 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis Completed · 163 cited
  19. Phase 4 Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis Completed · 162 cited
  20. Phase 4 MTX Discontinuation and Vaccine Response Completed · 139 cited
  21. Phase 3 A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy Completed · 133 cited
  22. Phase 3 A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment Completed · 131 cited
  23. Phase 4 Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis. Completed · 129 cited
  24. Phase 4 Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants Completed · 125 cited
  25. Phase 3 To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) Completed · 125 cited
  26. Phase 3 Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis Completed · 121 cited
  27. Phase 4 COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA Completed · 114 cited
  28. Phase 3 A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) Completed · 108 cited
  29. Phase 3 A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs Completed · 108 cited
  30. Phase 3 A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy Completed · 106 cited
  31. Phase 3 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis Completed · 102 cited
  32. Phase 3 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Completed · 88 cited
  33. Phase 3 A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Completed · 82 cited
  34. Phase 3 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Completed · 80 cited
  35. Phase 3 Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) Completed · 79 cited
  36. Phase 4 Treatments Against RA and Effect on FDG-PET/CT Completed · 74 cited
  37. Phase 3 Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Completed · 73 cited
  38. Phase 4 IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA Completed · 72 cited
  39. Phase 3 PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease Completed · 72 cited
  40. Phase 3 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Completed · 70 cited
  41. Phase 3 A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) Completed · 66 cited
  42. Phase 3 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Completed · 65 cited
  43. Phase 3 Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients Completed · 62 cited
  44. Phase 3 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 60 cited

Showing the 50 most-cited and recently-updated of 781 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Rheumatoid Arthritis: what the trials found

Tofacitinib demonstrated significant reductions in Physician Global Evaluation of Disease Activity Scores across multiple patient cohorts, including sJIA1 (-4.44 to -5.33), sJIA2 (-4.39 to -5.24), and pJIA groups (up to -5.20) 1. CP-690,550 showed significant improvements in DAS28-4 (ESR) at week 48 compared to the comparator 17, while a placebo matched to prednisone resulted in significantly lower DAS28-ESR scores and higher treatment success rates compared to the placebo group 20.

Etanercept was associated with a statistically significant higher proportion of insufficient responders achieving remission (DAS28CRP < 2.6) at 28 weeks when using specific induction protocols 21. In contrast, Prednisolone was associated with significantly lower DAS28 scores and lower rates of joint damage progression compared to its comparator 16.

Certolizumab Pegol showed no significant difference in ACR20 achievement at week 12 or in the proportion of patients achieving remission (DAS28-ESR ≤ 3.2) at week 104 compared to the comparison arm 15. Methotrexate was evaluated for its impact on vascular inflammation, showing no significant difference in FDG-PET/CT measurements but reaching statistical significance in changes to the MDS and average TBR of the aorta [18, 22].

Recent results — preliminary, needs further review

  • • A multi-center study on combination vs. monotherapy showed comparable CDAI scores at 6 months for Tofacitinib monotherapy vs. Methotrexate combination and TNFi monotherapy vs. TNFi/Methotrexate combination 13. • An intervention involving education, a self-management app, and physiotherapy resulted in statistically significant improvements in Patient Activation Measure (p=0.05), RA Disease Activity Index (p=0.05), and pain scores (p=0.05) 8. • Clinical trials for 2-HOBA 3, SOL-116 4, Butyrate 5, and Mindfulness Programs 6 are ongoing or recently conducted. ․ Infliximab biosimilar 3 showed a range of DAS28 scores and remission rates in a recent study 12. ․ Surgical interventions (Persona Total Knee) and other treatments (Certolizumab, Phone-Based Walk With Ease) are currently under investigation or recently reported [7, 10, 11].

For the clinician treating this condition

  • Tofacitinib is associated with consistent reductions in physician-assessed disease activity across various juvenile idiopathic arthritis cohorts 1.
  • Prednisolone use was linked to lower joint damage progression and significantly improved DAS28 scores compared to the control group 16.
  • Etanercept showed superior rates of remission in specific induction protocols over standard methods 21.

AI synthesis of 13 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications
Rheumatology FDA Approval
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications FDA approves Hadlima, a new biosimilar for several inflammatory diseases.
The FDA approved Hadlima (adalimumab) for several inflammatory conditions including rheumatoid arthritis, juvenile idiopathic arthritis, pso…
The FDA approved Hadlima (adalimumab) for treating conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. It is a biosimilar,…
FDA May 5, 2026
Telephone-delivered Walk With Ease program recruitment strategies compared in adults with arthritis
Primary Care & Family Medicine RCT
Telephone-delivered Walk With Ease program recruitment strategies compared in adults with arthritis Radio ads and Facebook work best to recruit arthritis patients
This randomized trial in 267 adults with arthritis compared recruitment strategies for a telephone-delivered walking program. Facebook was t…
Radio ads and Facebook ads work best to get arthritis patients into walking programs, but the best method depends on who you are trying to r…
May 4, 2026
Meta-analysis of 38 rodent studies shows sinomenine reduces arthritis markers in preclinical models
Drug Pipeline Meta-analysis
Meta-analysis of 38 rodent studies shows sinomenine reduces arthritis markers in preclinical models Sinomenine reduces joint swelling and inflammation in arthritis mice
This systematic review and meta-analysis evaluates sinomenine in 38 rodent models of rheumatoid arthritis. The authors synthesize data on in…
A new review shows sinomenine stops joint swelling and protects bone in mice, but doctors still need to test it on humans.
Frontiers May 4, 2026
Psoriatic arthritis linked to interstitial lung disease prevalence
Dermatology Meta-analysis
Psoriatic arthritis linked to interstitial lung disease prevalence Psoriatic Arthritis Patients Face Hidden Lung Risk Doctors Often Miss
A systematic review finds 3% of psoriatic arthritis patients have interstitial lung disease, with smoking increasing risk. Imaging-based dia…
Hidden lung scarring affects about 1 in 20 psoriatic arthritis patients, and smoking triples the risk, a new analysis shows.
May 2, 2026
Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations
Dermatology Meta-analysis
Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations Psoriasis drugs change heart risk in surprising ways
A comprehensive meta-analysis of 24,575 patients reveals that targeted therapies for psoriasis and psoriatic arthritis consistently modify l…
Some common psoriasis drugs sharply raise cholesterol while others lower it, forcing doctors to rethink how they protect their patients’ hea…
May 2, 2026
Systematic review explores the role of RNA methylation in autoimmune rheumatic diseases
Rheumatology Sys. Review
Systematic review explores the role of RNA methylation in autoimmune rheumatic diseases RNA Methylation Could Change How We Treat Joint Pain
This systematic review examines the impact of RNA methylation on various autoimmune rheumatic diseases, including rheumatoid arthritis and s…
A new review explains how tiny chemical tags on RNA control inflammation and could lead to better treatments for painful autoimmune diseases…
Frontiers May 2, 2026
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Rheumatology Meta-analysis
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
This meta-analysis reviewed data from over 5000 patients with late-onset rheumatoid arthritis (LORA) and young-onset rheumatoid arthritis (Y…
A large review found older patients with rheumatoid arthritis had higher disease activity and lower remission rates on biologics compared to…
May 1, 2026
Team-based care with rheumatological specialist assistants improved patient satisfaction in seropositive rheumatoid arthritis flares
Rheumatology RCT
Team-based care with rheumatological specialist assistants improved patient satisfaction in seropositive rheumatoid arthritis flares Team-based care boosts satisfaction for rheumatoid arthritis patients
This randomized controlled trial enrolled 224 patients with seropositive rheumatoid arthritis during flares across a multicenter setting.
Rheumatoid arthritis patients were more satisfied with care from a team led by specialist assistants than with standard rheumatologist visit…
May 1, 2026
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
Dermatology RCT
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis New drug ixekizumab shows promise for children with arthritis
This multicentre, open-label, phase 3 study evaluated ixekizumab in 101 children with enthesitis-related arthritis or juvenile psoriatic art…
A phase 3 study found ixekizumab helped many children with arthritis meet response criteria at week 16, with mostly mild side effects report…
May 1, 2026
Narrative review of transposable element methylation in autoimmune diseases
Diabetes & Endocrinology Sys. Review
Narrative review of transposable element methylation in autoimmune diseases Genetic elements may link autoimmune diseases to inflammation
This narrative review examines the role of transposable element (TE) methylation and expression in Type 1 diabetes, systemic lupus erythemat…
Changes in certain genetic elements could explain how the body triggers inflammation in diseases like lupus and rheumatoid arthritis.
Frontiers May 1, 2026
Systematic review and meta-analysis of diagnostic algorithms for rheumatoid arthritis and juvenile idiopathic arthritis
Rheumatology Meta-analysis
Systematic review and meta-analysis of diagnostic algorithms for rheumatoid arthritis and juvenile idiopathic arthritis How to spot arthritis in health records: a review of 35 studies
This systematic review and meta-analysis evaluates algorithms used to identify rheumatoid arthritis and juvenile idiopathic arthritis in ele…
A review of 35 studies finds that combining diagnosis codes with prescription data can accurately identify rheumatoid arthritis in electroni…
May 1, 2026
High-intensity exercise improves strength and aerobic capacity in rheumatoid arthritis patients compared to low-intensity exercise
Rheumatology Meta-analysis
High-intensity exercise improves strength and aerobic capacity in rheumatoid arthritis patients compared to low-intensity exercise High-intensity exercise beats low-intensity exercise for strength and fitness in rheumatoid arthritis
This systematic review analyzed eleven clinical trials involving patients with rheumatoid arthritis to compare high-intensity versus low-int…
High-intensity exercise improved muscle strength and fitness better than low-intensity exercise for people with rheumatoid arthritis, with n…
May 1, 2026

Research across Arthritis

Related studies from across the Arthritis family.

Health literacy is moderately associated with improved self-care behaviors in patients with multiple chronic diseases
Primary Care & Family Medicine Meta-analysis
Health literacy is moderately associated with improved self-care behaviors in patients with multiple chronic diseases Better health literacy helps people manage chronic diseases more effectively
This meta-analysis of 138 studies found a moderate positive association (r = 0.29, 95% CI: 0.26-0.31) between health literacy and self-care …
Understanding medical information and using digital tools can help people with chronic conditions like diabetes or heart failure manage thei…
Jul 7, 2026
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome
Pediatrics Sys. Review
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome Two children with severe arthritis found relief using a new drug approach
This narrative review synthesizes a retrospective case series and literature search on ruxolitinib for systemic juvenile idiopathic arthriti…
Two children with severe arthritis complications found relief using a new drug approach, offering hope for those who struggle with standard …
Frontiers May 28, 2026
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis
Pediatrics Meta-analysis
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis Combination therapy reduces relapse risk in children with eye inflammation from arthritis
This systematic review and meta-analysis of RCTs evaluated adalimumab plus methotrexate in children with juvenile idiopathic arthritis-assoc…
Combining adalimumab with methotrexate lowers relapse risk and helps reduce steroid use in children with arthritis-related eye inflammation.
May 1, 2026
Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24
Drug Pipeline RCT
Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24 New Hope for Kids with Stubborn Eye Inflammation
This open-label, active-controlled phase-3 multicenter trial enrolled 30 pediatric patients with juvenile idiopathic arthritis-associated uv…
A new drug shows early promise for children with stubborn eye inflammation who didn't respond to standard treatments, offering hope when oth…
Apr 18, 2026

Questions about Rheumatoid Arthritis

Did baricitinib work well for juvenile idiopathic arthritis eye inflammation?

Baricitinib showed limited effectiveness for treating eye inflammation in children with juvenile idiopathic arthritis who did not respond to other standard treatments.

Full answer →
Can machine learning predict when juvenile idiopathic arthritis will go inactive?

Yes, machine learning models using registry data can predict inactive disease in juvenile idiopathic arthritis with about 70-76% accuracy, but they are not yet ready for routine clinical use.

Full answer →
Can Hadlima be used to treat juvenile idiopathic arthritis?

Yes, Hadlima (adalimumab) is FDA-approved to treat moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.

Full answer →
How does macrophage metabolism change in gouty arthritis patients?

In gouty arthritis, macrophages shift their energy use from oxidative phosphorylation to glycolysis and change from pro-inflammatory to anti-inflammatory states as the attack resolves.

Full answer →
Does quercetin work for gouty arthritis based on recent reviews?

Recent reviews suggest quercetin has anti-inflammatory and antioxidant properties that could help with gout, but there is currently no strong clinical proof it works for gouty arthritis in humans.

Full answer →
Why do current gouty arthritis models fail to match human disease?

Current gout models fail because they do not fully capture the complex metabolic changes in macrophages or the chronic, multi-factorial nature of human disease.

Full answer →
How is Arthritis Awareness Month observed to highlight the condition's impact?

Arthritis Awareness Month is observed in May to bring attention to the condition and its impact on daily life.

Full answer →
What percentage of U.S. adults with arthritis engage in physical activity?

About 67% of U.S. adults with arthritis engage in at least one type of physical activity, though many do not meet full health guidelines.

Full answer →
See all 21 questions about Rheumatoid Arthritis →